GLP-1/GIP dual agonist tirzepatide normalizes diabetic nephropathy via PI3K/AKT mediated suppression of oxidative stress
These findings expand the potential effects and mechanics of tirzepatide in the treatment of DN, which may provide a novel therapeutic approach and therapeutic target for DN treatment.
Authors
- Ye Guo (ORCID: https://orcid.org/0000-0002-1813-9815)
- Ruixue Tian
- Baodong Wang (ORCID: https://orcid.org/0000-0002-1323-1372)
- Yan Pan (ORCID: https://orcid.org/0000-0002-4546-2351)
- Juan He (ORCID: https://orcid.org/0009-0008-8406-1463)
- Yan Tian
- Yao Cheng
- Rongshan Li (ORCID: https://orcid.org/0000-0002-4311-8565)
Institutions
- Shanxi Medical University (CN)
- Jinzhong University (CN)
Publication Details
- Journal
- International Immunopharmacology
- Published
- 2024-12-18
- DOI
- https://doi.org/10.1016/j.intimp.2024.113877
- Citations
- 7
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 2.50